Showing results (71-80 of 144) with videos related to
Sort By:
Pageof 15
International Journal of Cancer|August 12, 2009
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United StatesShu-Yuan Liao, William H Rodgers, James Kauderer, et al.Gynecologic Oncology|December 3, 2005
Preoperative predictors of positive margins after loop electrosurgical excisional procedure-ConeTodd D Tillmanns, Camille A Falkner, David B Engle, et al.Gynecologic Oncology|February 1, 2011
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group studyMark A Morgan, Michael W Sill, Keiichi Fujiwara, et al.Journal of Clinical Microbiology|December 1, 2012
Reproducibility of linear array for human papillomavirus genotypingJill Koshiol, S Terence Dunn, Joan L Walker, et al.Cancer|February 25, 2009
Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population?Kathleen N Moore, Summer G Frank, Erin K Alward, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyBradley J Monk, Michael W Sill, Joan L Walker, et al.Gynecologic Oncology|October 11, 2005
Carcinosarcoma of the ovary-a case seriesTeresa L Rutledge, Michael A Gold, D Scott McMeekin, et al.Cancer Investigation|December 14, 2011
Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individualsJames R Hocker, Erin A Bishop, Stan A Lightfoot, et al.Gynecologic Oncology|December 14, 2011
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group studyNatalie Gould, Michael W Sill, Robert S Mannel, et al.Gynecologic Oncology|July 29, 2015
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG studyJames S Ferriss, James J Java, Michael A Bookman, et al.Pageof 15